Rasna Therapeutics, Inc. (RASP) financial statements (2020 and earlier)

Company profile

Business Address 420 LEXINGTON AVENUE
NEW YORK, NY 10170
State of Incorp. NV
Fiscal Year End September 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2019
TTM
9/30/2019
9/30/2018
3/31/2017
6/30/2016
6/30/2015
6/30/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2850434,049006
Cash and cash equivalents2850434,049006
Receivables 1423885   
Other undisclosed current assets876766   
Total current assets:36723474,200006
Noncurrent Assets
Property, plant and equipment2257   
Intangible assets, net (including goodwill)4,8722,9592,9592,959  
Goodwill2,7232,7232,7232,723   
Intangible assets, net (excluding goodwill)2,149236236236   
Other undisclosed noncurrent assets 1,9131,9131,913000
Total noncurrent assets:4,8744,8744,8784,879000
TOTAL ASSETS:4,9104,9465,2259,079007
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1,5931,5911,4229035440
Accounts payable 864720549 40
Accrued liabilities 72770235452  
Taxes payable    2  
Other undisclosed accounts payable and accrued liabilities1,593   0  
Debt331   9 1
Due to related parties556550550625107 
Other undisclosed current liabilities 265137   (0)
Total current liabilities:2,4802,4052,1091,52873111
Noncurrent Liabilities
Liabilities, other than long-term debt  11    
Deferred tax liabilities, net11    
Other undisclosed noncurrent liabilities33    0
Total noncurrent liabilities:3311   0
Total liabilities:2,4832,4092,1201,52873111
Stockholders' equity
Stockholders' equity attributable to parent, including:2,4262,5373,1067,551(72)(11)6
Common stock69696968333
Additional paid in capital19,82719,78019,41216,741484848
Accumulated deficit(17,470)(17,312)(16,375)(9,258)(123)(62) 
Other undisclosed stockholders' equity attributable to parent      (45)
Total stockholders' equity:2,4262,5373,1067,551(72)(11)6
TOTAL LIABILITIES AND EQUITY:4,9104,9465,2259,079007

Income statement (P&L) ($ in thousands)

12/31/2019
TTM
9/30/2019
9/30/2018
3/31/2017
6/30/2016
6/30/2015
6/30/2014
Operating expenses(665)(915)(4,070)(4,535)(62)(17)(40)
Operating loss:(665)(915)(4,070)(4,535)(62)(17)(40)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(36)(29)(4)101   
Interest and debt expense(36)(28)     
Other undisclosed income from continuing operations before equity method investments, income taxes9      
Loss from continuing operations before equity method investments, income taxes:(728)(972)(4,074)(4,434)(62)(17)(40)
Other undisclosed income from continuing operations before income taxes2828     
Loss from continuing operations before income taxes:(701)(944)(4,074)(4,434)(62)(17)(40)
Income tax expense (benefit) 8(2)628   
Other undisclosed income from continuing operations8      
Net loss:(693)(936)(4,076)(3,806)(62)(17)(40)
Other undisclosed net loss attributable to parent   (628)   
Net loss available to common stockholders, diluted:(693)(936)(4,076)(4,434)(62)(17)(40)

Comprehensive Income ($ in thousands)

12/31/2019
TTM
9/30/2019
9/30/2018
3/31/2017
6/30/2016
6/30/2015
6/30/2014
Net loss:(693)(936)(4,076)(3,806)(62)(17)(40)
Comprehensive loss, net of tax, attributable to parent:(693)(936)(4,076)(3,806)(62)(17)(40)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: